I-American Cancer Society ilinganisela ukuthi abantu abangaphezu kuka-97,000 e-United States bazotholakala benomdlavuza we-colorectal kulo nyaka futhi bazobangela ukufa okulinganiselwa ku-50,600. Iwumdlavuza wesithathu ovame kakhulu e-United States futhi iyimbangela yesibili yokufa komdlavuza.
Nakuba ukuhlolwa komdlavuza we-colorectal kuboniswe kuphumelela ekwehliseni ukufa komdlavuza, abacwaningi babika ukuthi isibalo sabahlola sincane kakhulu. Iziqondiso zamanje ze-ACS zincoma ukuhlolwa okujwayelekile kwamaqembu asengozini evamile eneminyaka engu-45 nangaphezulu, kusetshenziswa ukuhlolwa kwe-fecal okuzwela kakhulu noma ukuhlolwa kwesakhiwo (okubonwayo), futhi yonke imiphumela emihle kufanele ibe i-colonoscopy. Naphezu kwalezi zincomo, ucwaningo lwathola umehluko omkhulu emazingeni okuhlola, okuhlanganisa ubuhlanga, indawo yezwe, nezinye izici zenhlalo-mnotho.
Kusukela umdlavuza colorectal is a preventable disease, efforts are being made throughout the country to increase the screening rate of colorectal cancer, but the screening rate is only about 63%, while the screening rate of low-income and other vulnerable groups is often lower.
The latest research suggests that with stool immunochemical tests, or FIT kits, they can detect blood in stool and common symptoms of colon cancer. The patient can complete the test at home and return it to the provider for analysis. Patients with a positive result of the FIT kit test will be scheduled for colonoscopy.
Ocwaningweni, iziguli ezingama-21% ezithola ikhithi ye-FIT ziphothule ukuhlolwa kokuhlolwa, kwathi abantu abangu-18 abaphothule ukuhlolwa kwe-FIT bathola imiphumela engajwayelekile, kwathi abangu-15 kubo badinga i-colonoscopy. Ezigulini eziyi-10 eziqede ikholonoscopy, isiguli esingu-1 sibe nemiphumela engajwayelekile.
Abaphenyi bahlela ukuqhubeka nokutadisha ukuthi le ndlela yokuthola ingasetshenziswa yini ngezinga elikhudlwana futhi bafunde kabanzi ngokusebenza kahle kwezindleko nokuthi bangalinyusa kanjani izinga lokuhlolwa kwamaqembu asengozini.
